Pediatric Vaccine Market to Surpass US$ 98,859.3 Million by 2027

Vaccination is required to protect infants from various diseases such as pneumonia, polio, and influenza. Vaccination imitates a particular pathogen (infection causing organism) and triggers the body’s immune system to produce the requisite antibodies that in future develop resistance towards infections caused by these pathogens.

Read report Overview @ https://www.coherentmarketinsights.com/market-insight/pediatric-vaccines-market-1708

R&D of new vaccines is expected to offer lucrative growth opportunities for players in the global pediatric vaccines market. For instance, in April 2018, Merck & Co, Inc. initiated two Phase III studies of PCV-15 (V114), an investigational polyvalent conjugate vaccine for the prevention of pneumococcal disease.

Market players can also focus on developing vaccines for diseases such as West Nile virus and Zika. As of April 2019, no vaccines have been approved for clinical use, however a number of vaccines are currently in clinical trials such as NAbs, neutralizing antibodies and ZPIV, ZIKV purified inactivated virus vaccine.

Pneumococcal Vaccine sub segment in the vaccine type segment in global pediatric vaccines market was valued at US$ 10,299.7 Mn in 2018 and is expected to reach US$ 36,120.1 Mn by 2027 at a CAGR of 14.4% during the forecast period.

Request PDF Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/1708

Major players operating in the global pediatric vaccine market include GlaxoSmithKline Plc., Merck & Co., Inc., Pfizer Inc., Sanofi S.A., Panacea Biotec, Zydus Cadila, Emergent BioSolutions Inc., Serum Institute of India Pvt. Ltd., Bharat Biotech, and Indian Immunologicals Ltd.

Global Pediatric Vaccine Market: Key Developments

Major players in the market are also focused on developing new vaccines to expand their product portfolio. For instance, in December 2019, NewLink Genetics Corporation received the U.S. FDA approval for ERVEBO or Zaire Ebola virus vaccine V920.

Major players in the market are focused on conducting clinical trials to expand their product portfolio. For instance, in December 2019, Soligenix, Inc. initiated the study to assess the Safety of RiVax, a lyophilized ricin toxin A-chain subunit vaccine with alum-adjuvant.

Free Sample Report + All Related Graphs & Charts @ https://www.coherentmarketinsights.com/insight/request-sample/1708 

Detailed Segmentation

Global Pediatric Vaccines Market, By Vaccine Type:
Pneumonococcal Vaccine
DTP Vaccine
Rotavirus Vaccine
MMR Vaccine
Polio Vaccine
Influenza Vaccine
Hepatitis B Vaccine
Meningococcal Vaccine
Hib Vaccine
Varicella Vaccine
Global Pediatric Vaccines Market, By Technology:
Live or Attenuated Vaccine
Inactivated or Killed Vaccine
Toxoid Vaccine
Conjugate Vaccine
Subunit Vaccine
Recombinant Vaccine
Global Pediatric Vaccines Market, By Type:
Monovalent Vaccine
Multivalent Vaccine
Global Pediatric Vaccines Market, By Distribution Channel:
Government
Private

Coherent Market Insights 1001 4th Ave,
#3200 Seattle, WA 98154,U.S.
Phone: US +1-206-701-6702/UK +44-020 8133 4027
Email: sales@coherentmarketinsights.com

About Us:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

This release was published on openPR.